ACZONE® (dapsone) Gel, 7.5% Recognized With Teen Vogue Acne Award Win

DUBLIN, Sept. 26, 2017 /PRNewswire/ -- Today, Allergan plc (NYSE: AGN) is pleased to announce that ACZONE^® (dapsone) Gel, 7.5%, a prescription medicine used on the skin (topical) to treat acne in people 12 years and older, has received a Teen Vogue Acne Award for "Best Prescription Product."  This is the first year that Teen Vogue, a publication regarded as an information destination for the next generation, known for empowering young, millennial women to lead stylish, healthy and informed lives, has honored acne-fighting products on the market with its own dedicated awards. The introduction of these awards further demonstrates the prevalence of acne among the outlet's readership and young adult women, with the piece highlighting "anti-acne as one of the most searched terms on the web," and that "Google searches with the word acne drove 75,000 clicks" to the publication's website this summer alone. 

"We are proud to be recognized by Teen Vogue as the only prescription product within a competitive and crowded category," said Marc Forth, Senior Vice President, U.S. Neurosciences/Urology & Medical Dermatology at Allergan. "This win further reinforces Allergan's commitment to bold product development and innovation to serve growing consumer needs within the medical dermatology community." 

Award winners were vetted by the industry's top skin care experts, including dermatologists and celebrity aestheticians, alongside the Teen Vogue editorial team to determine the winners in each category.  ACZONE^® (dapsone) Gel, 7.5% was highlighted by Teen Vogue for its unique dapsone ingredient, recognized as a topical prescription acne treatment that can help clear skin.

This accolade marks the first editorial award win for the 7.5% formula which launched last year. Since its introduction, ACZONE^®(dapsone) Gel, 7.5% has continued to gain recognition among the dermatological community, further solidifying Allergan's prominence within medical dermatology. 

The full list of 2017 Acne Award winners can be viewed on TeenVogue.com.

ACZONE^® (dapsone) Gel, 7.5% Important Safety Information

Indication  
ACZONE^® Gel, 7.5% is approved by the U.S. Food and Drug Administration (FDA) as a prescription medicine used on the skin (topical) to treat acne in people 12 years of age and older.¹

Important Safety Information

Before you use ACZONE^®, tell your doctor about all of your medical conditions, including if you have: glucose-6-phosphate dehydrogenase deficiency (G6PD) or higher than normal levels of methemoglobin in your blood (methemoglobinemia).

Talk to your doctor about any medications you're using including topical benzoyl peroxide (BPO). Use of BPO with ACZONE^® Gel may cause your skin and facial hair to temporarily turn yellow or orange at the site of application.

ACZONE^® Gel 7.5% may cause serious side effects, including:

• A decrease of oxygen in your blood caused by a certain type of abnormal red blood cell (methemoglobinemia). If your lips, nail beds or the inside of your mouth turns grey or blue, stop using ACZONE^® Gel 7.5% and get medical help right away.
• A breakdown of red blood cells (hemolytic anemia) for some people with G6PD deficiency using ACZONE^® Gel 7.5%.
• Stop using ACZONE^® Gel 7.5%, and call your doctor right away if you get any of the following signs and symptoms: back pain, breathlessness, tiredness/weakness, dark-brown urine, fever, or yellow or pale skin.

The most common side effects of ACZONE® Gel 7.5% are dryness and itching of the skin being treated.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Product Information for  ACZONE^®

¹ACZONE® (dapsone) Gel 7.5% U.S. Prescribing Information

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners.

CONTACTS: 

Allergan: 
Investors: 
Daphne Karydas  
(862) 261-8006

Media: 
Mark Marmur 
(862) 261-7558  

Lisa Kim  
(714) 246-3843

SOURCE Allergan plc

Related Links

http://www.allergan.com